Publications

HUPO 2024 Poster: Development of NULISAseq™ Inflammation Panel 250 for Comprehensive Immune Profiling

Product:

Topic:

Disease Area:

Sample Type:

Topic/Product:

Disease Area:

Sample Type:

Abstract

Comprehensive profiling of cytokines and chemokines in blood can provide deeper insights into the mechanisms underlying highly complex and heterogeneous groups of autoimmune diseases. However, many of these proteins are present at very low concentrations in plasma, below the limit of detection of current immunoassays. We recently developed an automated multiplex immunoassay technology, NULISA™, capable of attomolar-level sensitivity and high levels of multiplexing, and we demonstrated the performance characteristics of a 200-plex assay and its correlation with existing platforms2. Here we report the development of an expanded inflammation-focused panel called NULISAseq™ Inflammation Panel 250 (IP250) targeting 200 cytokines/chemokines and their receptors and 50 other important inflammation and immune response-related proteins. The assay demonstrated high sensitivity, detecting 97.6% of the targets in at least 50% of plasma samples, and high precision, with median intra-plate CV of <15% and inter-plate CV of <15%. It also demonstrated the ability to quantify proteins of a wide dynamic range without diluting samples. Comprehensive testing for target specificity demonstrated that 95% of the assays in the panel had <1% cross reactivity to nonspecific targets. In summary, with ultrahigh sensitivity and the most comprehensive coverage of inflammatory cytokines/chemokines, the Inflammation Panel 250 assay provides a powerful discovery tool for inflammation and immunology research at the systems level, which may lead to new diagnostic biomarkers and therapeutic targets.

Authors & Affiliations

Xiao-Jun Ma1, Qinyu Hao1, Helena Sun1, Vasudha Murlidhar1, Anna Lee1, Ming Yu1, Ishara Ariyapala1, Sean Kim1, Joanne Beer1, Wei Feng1, Dwight Kuo1, Bingqing Zhang1, Lei Fang1, Yuling Luo1

1Alamar Biosciences Inc., Fremont, California, USA

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.